JERUSALEM

耶路撒冷

,

，

October 14, 2026

2026年10月14日

/PRNewswire/ --

/美通社/ --

Scinai Immunotherapeutics Ltd.

Scinai免疫疗法有限公司

(NASDAQ:

（纳斯达克：

SCNI

SCNI

) ('Scinai' or the 'Company'), a biopharmaceutical company operating a growing contract development and manufacturing organization ('CDMO') alongside an immunology-focused therapeutic development platform, today announced that it has entered into a securities purchase agreement with an existing life sciences institutional investor for the purchase and sale of 2,458,334 American Depositary Shares ('ADSs') (or pre-funded warrants in lieu thereof), each ADS representing 40,000 ordinary shares, .

Scinai（以下简称“公司”）是一家生物制药公司，运营着一家不断发展的合同开发与制造组织（CDMO），并拥有一个专注于免疫学的治疗开发平台。该公司今日宣布，已与一家现有的生命科学机构投资者签订证券购买协议，以买卖2,458,334股美国存托股份（ADS）（或替代的预融资权证），每股ADS代表40,000股普通股。

together with Series A-1 warrants to purchase up to 3,687,501 ADSs, at an exercise price of $1.20 per ADS, exercisable immediately with a term of five years,

连同A-1系列认股权证，该等权证允许以每美国存托股份（ADS）1.20美元的行权价格购买最多3,687,501股ADS，可立即行权，期限为五年，

at a combined purchase price of $1.20 per ADS and accompanying warrants (or $1.1999 per pre-funded warrant and accompanying warrants). Each pre-funded warrant will have a remaining exercise price of $0.0001 per ADS.

每份美国存托凭证（ADS）及附随认股权证的合并购买价格为1.20美元（或每份预付资金认股权证及附随认股权证的合并购买价格为1.1999美元）。每份预付资金认股权证的剩余行权价格为每份美国存托凭证0.0001美元。

In addition, the Company entered into a warrant inducement agreement with the same investor for the immediate cash exercise of warrants issued in April 2026 to purchase an aggregate of 879,194 ADSs (the 'Existing Warrants') at a reduced exercise price of $1.20 per ADS.

此外，公司与同一投资者签订了一份认股权证诱导协议，以立即现金行权的方式行使2026年4月发行的认股权证（“现有认股权证”），以每股美国存托股份（ADS）1.20美元的降低行权价购买总计879,194股美国存托股份。

In consideration for the immediate exercise in full of the Existing Warrants for cash, the investor will receive in a private placement new unregistered Series A-1 warrants to purchase up to 1,318,791 ADSs (the 'New Warrants'). The New Warrants will have an exercise price of $1.20 per ADS, will be exercisable immediately, and will expire five (5) years from the date of issuance..

作为对投资者以现金立即全额行使现有认股权证的对价，投资者将在一次私募中获得新的未注册A-1系列认股权证，该等认股权证可用于购买最多1,318,791股美国存托股份（“新认股权证”）。新认股权证的行权价格为每股美国存托股份1.20美元，可立即行权，并自发行之日起五（5）年后到期。

The aggregate gross proceeds from the private placement and the warrant inducement transaction are expected to be approximately $4.0 million, before deducting placement agent fees and expenses. These proceeds exclude any future proceeds from the exercise of the newly issued Series A-1 warrants. The closing of the transactions is expected to occur on or about October 15, 2026, subject to satisfaction of customary closing conditions..

在扣除配售代理费用及开支前，预计来自私募配售及认股权证诱导交易的总收益约为400万美元。该等收益不包括行使新发行的A-1系列认股权证所产生的任何未来收益。交易交割预计将于2026年10月15日左右进行，但须满足惯常的交割条件。

Scinai intends to use the net proceeds, together with existing cash resources, to support the expansion of its CDMO platform, advance customer programs, and continue selective investment in its immunotherapy pipeline. The Company believes this financing will support the execution of its growth strategy..

Scinai 计划将净收益与现有现金资源一起，用于支持其 CDMO 平台的扩张、推进客户项目，并继续对其免疫治疗管线进行选择性投资。公司相信，此次融资将有助于其增长战略的实施。

A.G.P./Alliance Global Partners is acting as the sole placement agent for the transactions.

A.G.P./Alliance Global Partners 担任本次交易的独家配售代理。

The ADSs issuable upon exercise of the Existing Warrants have been registered for resale pursuant to the Company's effective registration statement on Form F-3 (File No. 333-295698). The ADSs and warrants offered in the private placement, the New Warrants and the securities underlying those warrants have not been registered under the Securities Act of 1933, as amended (the 'Securities Act'), or applicable state securities laws.

根据本公司生效的F-3表格注册声明（档案编号：333-295698），行使现有认股权证时可发行的美国存托股份已登记用于转售。在私募配售中发售的美国存托股份和认股权证、新认股权证以及这些认股权证项下的基础证券，均未根据经修订的《1933年证券法》（“《证券法》”）或适用的州证券法进行注册。

The offer and sale of the securities in the private placement and the New Warrants will be made in reliance on an exemption from registration under Section 4(a)(2) of the Securities Act and Regulation D promulgated thereunder. Accordingly, these unregistered securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.

本次私募中证券的发行与销售以及新权证的发行与销售，将依据《证券法》第4(a)(2)条及其下颁布的D条例所规定的注册豁免进行。因此，这些未经注册的证券不得在美国境内发行或销售，除非依据有效的注册声明，或符合《证券法》及相关州证券法规定的注册要求之适用豁免。

The Company has agreed to file a registration statement with the SEC to register for resale the ADSs issued in the private placement, the ADSs issuable upon exercise of the pre-funded warrants and New Warrants, and the underlying ordinary shares..

公司已同意向美国证券交易委员会提交注册声明，以登记以下证券的转售：私募配售中发行的美国存托股份（ADS）、行使预付认股权证及新认股权证时可发行的美国存托股份（ADS），以及其基础普通股。

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction..

本新闻稿不构成出售任何所述证券的要约，也不构成购买任何所述证券的要约邀请；在任何州或其他司法管辖区，若在该等州或司法管辖区的证券法下完成注册或资格认定之前，此类要约、要约邀请或销售行为属违法，则不得在该等州或司法管辖区进行上述证券的销售。

About Scinai Immunotherapeutics

关于 Scinai 免疫疗法公司

Scinai Immunotherapeutics Ltd.

Scinai免疫治疗有限公司

(Nasdaq:

（纳斯达克：

SCNI

SCNI

) is a biopharmaceutical company operating a growing contract development and manufacturing organization alongside an immunology-focused therapeutic development platform.

）是一家生物制药公司，运营着一家不断增长的合同开发与制造组织（CDMO），并拥有一个专注于免疫学的治疗开发平台。

Through its wholly owned subsidiary,

通过其全资子公司，

Scinai Biopharma Services Ltd.

Scinai生物制药服务有限公司

, the Company provides development and manufacturing services to biotechnology and pharmaceutical companies at its facilities in Jerusalem and Yavne, Israel. Scinai also advances its NanoAb platform through research collaboration and license arrangements with the Max Planck Society and University Medical Center Göttingen, both in Germany..

该公司在其位于以色列耶路撒冷和亚夫内的设施中，为生物技术和制药公司提供开发和制造服务。Scinai还通过与德国马克斯·普朗克学会和哥廷根大学医学中心的研究合作及许可安排，推进其NanoAb平台的发展。

For more information, please visit:

更多信息，请访问：

www.scinai.com

www.scinai.com

Company Contacts

公司联系人

Business Development | +972 8 930 2529 |

业务发展 | +972 8 930 2529 |

[email protected]

[email protected]

Investor Relations, Allele Capital Partners | Brian DeBeer | +1 (561) 388-8178 |

投资者关系，Allele Capital Partners | Brian DeBeer | +1 (561) 388-8178 |

[email protected]

[email protected]

Forward-Looking Statements

前瞻性陈述

This press release contains forward-looking statements under applicable U.S. securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among other things, statements regarding the timing and completion of the private placement and warrant inducement, the expected gross proceeds, the anticipated use of proceeds and the expected benefits of the financing..

本新闻稿包含根据美国适用证券法（包括1995年《私人证券诉讼改革法案》）界定的前瞻性陈述。前瞻性陈述包括但不限于有关私募配售及认股权证激励的 timing 和完成时间、预期募集资金总额、募集资金的预期用途以及融资的预期益处的陈述。

Actual outcomes may differ materially from current expectations. Relevant risks include the risk that one or both transactions may not close on the anticipated terms or timetable, or at all; technical, analytical, manufacturing, quality or regulatory difficulties; delays in equipment, materials or third-party services which can lead to delays in payments; changes in customer requirements or development plans; contractual modification or termination; delayed payments; failure to meet milestones; and differences between anticipated billings, cash collections and recognized revenue.

实际结果可能与当前预期存在重大差异。相关风险包括：一项或两项交易可能无法按预期的条款或时间表完成，甚至根本无法完成；技术、分析、制造、质量或监管方面的困难；设备、材料或第三方服务的延迟可能导致付款延迟；客户需求或开发计划的变更；合同的修改或终止；付款延迟；未能达成里程碑；以及预期开票金额、现金收款和确认收入之间的差异。

Additional risks include financing requirements, market conditions, competition, geopolitical conditions and the other risks described in the Company's Annual Report on Form 20-F and subsequent filings with the U.S. Securities and Exchange Commission..

其他风险包括融资需求、市场状况、竞争、地缘政治状况以及公司20-F表格年度报告和随后向美国证券交易委员会提交的文件中描述的其他风险。

Forward-looking statements reflect expectations as of the date of this release. Scinai undertakes no obligation to update them except as required by law.

前瞻性陈述反映了本发布日期的预期。Scinai 除法律要求外，不承担更新这些陈述的义务。

SOURCE Scinai Immunotherapeutics Ltd.

来源：Scinai Immunotherapeutics Ltd.

21

二十一

%

%

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示